Trial
NCT04992273
COVID-19 Administration of Single-Dose Subcutaneous Anti- Spike(s) SARS-CoV-2 Monoclonal Antibodies Casirivimab and Imdevimab in High-Risk Pediatric Participants Under 12 Years of Age
Phase IITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Regeneron Pharmaceuticals
Collaborators
—
Condition
COVID-19
Intervention
casirivimab+imdevimab
Why stopped
Emerging SARS-CoV-2 variants impacting susceptibility to study drug
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-10-20